Sanuwave Health Inc Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)1.23 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $4.62Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $39.7M Enterprise Value $54.3M Shares Outstanding 8.6M diluted Next Earnings Date6 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary SANUWAVE Health, Inc. (NASDAQ: SNWV) is a specialty medical device company focused on advanced wound care through its patented directed energy systems, primarily the UltraMIST system. The company utilizes a highly attractive 'razor/razor blade' recurring revenue model, where durable UltraMIST generators drive high-margin, single-use applicator consumable sales. While SANUWAVE achieved record annual revenues of $44.1 million in 2025 (up 35% YoY) and turned Adjusted EBITDA positive, near-term headwinds have emerged in 2026. Specifically, changes in CMS reimbursement for skin substitutes and subsequent clawbacks have caused a market freeze, leading to wound-care clinic closures and a surge in used equipment availability. This has severely pressured new capital equipment sales, forcing management to cut Q2 2026 revenue guidance to $8.5–$9.5 million. Although consumable volumes remain robust and on pace for record quarters, the near-term capital sales deceleration and swing back to a GAAP operating loss in Q1 2026 warrant a cautious Hold stance until market conditions stabilize. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The bear case reflects prolonged capital equipment market weakness, where used system sales continue to cannibalize new system demand. Additionally, if CMS clawbacks or further regulatory changes negatively impact consumable reimbursement rates, gross margins will compress, and the company's cash burn will accelerate, raising liquidity concerns. Base CaseCentral scenario The base case assumes that while capital equipment sales remain soft due to used system cannibalization and clinic closures, the high-margin recurring consumables business (representing the majority of revenues) continues to grow at a double-digit pace. The company navigates the CMS regulatory transition, and overall revenue growth stabilizes in the second half of 2026 as practitioners adapt to the new reimbursement landscape. Bull CaseUpside scenario The bull case relies on rapid stabilization of the capital equipment market, successful onboarding of Healogics iSupply GPO locations, and continued record-breaking consumable applicator volumes driving high-margin recurring revenue. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |